Yonsei University
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Private
- Established
- 1885-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.yonsei.ac.kr
The Effects of Jerusalem Artichoke and Fermented Soybean Powder Mixture Supplementation on Glucose Control
Not Applicable
Completed
- Conditions
- Newly Diagnosed Type 2 DiabetesPrediabetes
- Interventions
- Dietary Supplement: placeboDietary Supplement: jerusalem artichoke and fermented soybeans powder mixture
- First Posted Date
- 2015-07-23
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 60
- Registration Number
- NCT02506582
Effect of Midazolam Premedication on the Satisfaction Levels of Patients After Endoscopic Submucosal Dissection
Not Applicable
Completed
- Conditions
- Early Gastric CancerGastric Adenoma
- Interventions
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2016-03-07
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 72
- Registration Number
- NCT02504164
- Locations
- 🇰🇷
Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institue, Yonsei Universiy College of Medicine, Seoul, Korea, Republic of
A Comparison of Propofol Based Total Intravenous Anesthesia and Desflurane Based Balanced Anesthesia on Hepatic Protection During Living-donor Liver Transplantation
Phase 4
Completed
- Conditions
- End Stage Liver Disease
- Interventions
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 136
- Registration Number
- NCT02504138
- Locations
- 🇰🇷
Department of Anesthesiology and Pain Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of
Clinical Trial for Optimal Novel Oral Anticoagulant (NOAC) Schedule Immediate Before Catheter Ablation for Atrial Fibrillation
Not Applicable
- Conditions
- Atrial Fibrillation
- Interventions
- Drug: novel oral anticoagulant for 30 daysDrug: novel oral anticoagulant for 24 hour
- First Posted Date
- 2015-07-21
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 433
- Registration Number
- NCT02504177
- Locations
- 🇰🇷
Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea, Republic of
Regorafenib, C-kit Mutated Malignant Melanoma, 2nd Line Therapy
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2021-04-05
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 36
- Registration Number
- NCT02501551
- Locations
- 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
Afatinib, Paclitaxel, 2nd Line, Advanced Gastric Cancer
Phase 2
Completed
- Conditions
- Gastroesophageal Junction CancerGastric Cancer
- Interventions
- First Posted Date
- 2015-07-17
- Last Posted Date
- 2023-01-27
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 72
- Registration Number
- NCT02501603
- Locations
- 🇰🇷
Severance Hospital, Yonsei University Health System, Yonsei Cancer Center, Seoul, Korea, Republic of
Optimal Dose of Combination of Rocuronium and Cisatracurium
Not Applicable
Completed
- Conditions
- AnesthesiaChronic Otitis Media
- Interventions
- Drug: 10% reduction of combination of Esmeron® and Nimbex®Drug: 20% reduction of combination of Esmeron® and Nimbex®
- First Posted Date
- 2015-07-13
- Last Posted Date
- 2018-03-02
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 81
- Registration Number
- NCT02495038
A Trial of Imatinib for Patients With Aggressive Desmoid Tumor (Aggressive Fibromatosis)
- First Posted Date
- 2015-07-13
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 21
- Registration Number
- NCT02495519
- Locations
- 🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
S-1, Cisplatin-based Chemoradiotherapy, Induction Chemotherapy, Locally Advanced Gastric Adenocarcinoma
Phase 2
Completed
- Conditions
- Gastric Adenocarcinoma
- Interventions
- Drug: Induction DCS chemotherapy
- First Posted Date
- 2015-07-13
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 42
- Registration Number
- NCT02495493
- Locations
- 🇰🇷
Severance Hospital, Yonsei University Health System, Yonsei Cancer Center, Seoul, Korea, Republic of
Ticagrelor Monotherapy After 3 Months in the Patients Treated With New Generation Sirolimus Stent for Acute Coronary Syndrome (TICO Study)
Phase 4
- Conditions
- Acute Coronary Syndrome
- Interventions
- First Posted Date
- 2015-07-10
- Last Posted Date
- 2018-06-20
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 3056
- Registration Number
- NCT02494895
- Locations
- 🇰🇷
Division of Cardiology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath